Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 177Lu-J591 + Abiraterone + Prednisolone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
177Lu-J591 | Lu 177 rosopatamab tetraxetan|Lu 177 MOAB J591|177Lu-DOTA-TLX591 | PSMA Antibody 20 | 177Lu-J591 is a radioconjugate comprising the radionuclide lutetium-177 linked to a monoclonal antibody that targets PSMA (J591), which delivers radiation to PSMA-expressing tumor cells, potentially resulting in increased tumor cell death (PMID: 16203821). | |
Abiraterone | Zytiga | CB7630 | Hormone - Anti-androgens 54 | Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov). |
Prednisolone | Omnipred | Deltahydrocortisone |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|